At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR)
In Brief
A Phase 3 clinical trial evaluating Ticagrelor, ticagrelor, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 3,043 participants across 1 site.
Detailed Summary
Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.
Study Details
Timeline
Interventions
ticagrelor 45 mg twice daily for 5 consecutive days at least.
ticagrelor 90 mg once daily for 5 consecutive days at least.
ticagrelor 90 mg twice daily for 5 consecutive days at least.
clopidogrel 75 mg once daily for 5 consecutive days at least.